Search for a command to run...
Balaxi Pharmaceuticals Ltd. shows significant weaknesses in growth, profitability, and valuation metrics compared to its peers. Its negative revenue growth and return metrics indicate financial distress, making it a sector laggard in the trading industry. In contrast, companies like Adani Enterprises and Redington are strong performers with solid growth and profitability.
Stocks | CMP | Market Cap | P/E | ROCE (%) | Debt/Equity |
---|---|---|---|---|---|
BALAXI | - | - | 0.00 | 2.31% | 0.09 |
ADANIENT | ₹2,283.00 | ₹2,63,499.29Cr | 43.53 | 11.81% | 1.45 |
REDINGTON | ₹243.85 | ₹19,063.56Cr | 13.20 | 23.63% | 0.37 |
CPPLUS | ₹1,246.40 | ₹14,610.54Cr | 107.99 | 41.16% | 0.46 |
CELLO | ₹535.15 | ₹11,820.66Cr | 120.15 | 43.92% | 0.32 |
HONASA | ₹298.95 | ₹9,721.38Cr | 151.70 | 8.99% | - |
MMTC | ₹62.18 | ₹9,327.00Cr | 134.15 | 6.90% | - |